In a latest note to investors, a research analyst has provided a rating update for the Conglomerates sector company, Sunniva Inc (SNN). Analyst Matt Bottomley from Canaccord Genuity reiterated a Buy rating, with a C$10 price target yesterday.
According to TipRanks.com, Bottomley is a top 100 analyst with an average return of 41.0% and a 72.9% success rate. Bottomley covers the Healthcare sector, focusing on stocks such as Invictus MD Strategies Corporation, Aurora Cannabis Inc, and Sunniva Inc.
Read also: Tesla (TSLA) Deliveries: Underlying Demand Is All That Matters
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sunniva Inc with a C$10 average price target.
Sunniva Inc’s market cap is currently C$173.1M and has a P/E ratio of –. The company has a Price to Book ratio of 2.80.
Sunniva, Inc. is a development stage biopharmaceutical company. Through its subsidiaries, it engages in the provision of products and services to the medical cannabis industry in Canada and California. It also develops streamline data transfer software for physicians, patients, and producers.
The company’s shares closed last Monday at C$5.22.
